Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational drug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients whose HbA1c is between 7.5% and 10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are the excessive alcohol addicts~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teneli (Teneligliptin) /Teneli + insulin (Type: EXPERIMENTAL): Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
- Placebo/Teneli (Teneligliptin) + insulin (Type: PLACEBO_COMPARATOR): Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).